Report Content
Chapter 1 Methodology
1.1 Methodology
1.2 Market definitions
1.3 Forecast parameters
1.4 Data sources
1.4.1 Secondary
1.4.1.1 Paid sources
1.4.1.2 Unpaid sources
1.4.2 Primary
Chapter 2 Executive Summary
2.1 Cystic fibrosis therapeutics industry 360° synopsis, 2016 – 2027
2.1.1 Business trends
2.1.2 Treatment method trends
2.1.3 Distribution channel trends
2.1.4 Regional trends
Chapter 3 Cystic Fibrosis Therapeutics Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2016 - 2027
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Rise in incidence of cystic fibrosis
3.3.1.2 Advancements in therapeutics for treatment of cystic fibrosis in developed regions
3.3.1.3 Rising awareness and adoption of treatment procedures developing regions
3.3.2 Industry pitfalls and challenges
3.3.2.1 Low awareness in developing nations
3.3.2.2 High cost of surgical treatment
3.4 Growth potential analysis
3.4.1 By treatment method
3.4.2 By distribution channel
3.5 COVID-19 impact analysis
3.6 Porter’s analysis
3.7 Competitive landscape, 2020
3.7.1 Competitive matrix analysis, 2020
3.8 PESTEL analysis
Chapter 4 Cystic Fibrosis Therapeutics Market, By Treatment Method
4.1 Key segment trends
4.2 Medications
4.2.1 Market size, by region, 2016 – 2027
4.2.2 Market size, by Drug class, 2016 – 2027
4.2.2.1 CFTR modulators
4.2.2.1.1 Market size, by region, 2016 – 2027
4.2.2.2 Mucolytics
4.2.2.2.1 Market size, by region, 2016 – 2027
4.2.2.3 Bronchodilators
4.2.2.3.1 Market size, by region, 2016 – 2027
4.2.2.4 Pancreatic enzyme supplements
4.2.2.4.1 Market size, by region, 2016 – 2027
4.2.2.5 Others
4.2.2.5.1 Market size, by region, 2016 – 2027
4.2.3 Market Size, by route of administration, 2016 – 2027
4.2.3.1 Oral drugs
4.2.3.1.1 Market size, by region, 2016 – 2027
4.2.3.2 Inhaled drugs
4.2.3.2.1 Market size, by region, 2016 – 2027
4.3 Devices
4.3.1 Market size, by region, 2016 – 2027
4.4 Others
4.4.1 Market size, by region, 2016 – 2027
Chapter 5 Cystic Fibrosis Therapeutics Market, By Distribution Channel
5.1 Key segment trends
5.2 Hospitals
5.2.1 Market size, by region, 2016 – 2027
5.3 Retail pharmacies
5.3.1 Market size, by region, 2016 – 2027
5.4 Others
5.4.1 Market size, by region, 2016 – 2027
Chapter 6 Cystic Fibrosis Therapeutics Market, By Region
6.1 Key regional trends
6.2 North America
6.2.1 Market size, by country, 2016 – 2027
6.2.2 Market size, by treatment method, 2016 – 2027
6.2.2.1 Medications market size, by drug class, 2016 – 2027
6.2.2.2 Medications market size, by route of administration, 2016 – 2027
6.2.3 Market size, by distribution channel, 2016 – 2027
6.2.4 U.S.
6.2.4.1 Market size, by treatment method, 2016 – 2027
6.2.4.1.1 Medications market size, by drug class, 2016 – 2027
6.2.4.1.2 Medications market size, by route of administration, 2016 – 2027
6.2.4.2 Market size, by distribution channel, 2016 – 2027
6.2.5 Canada
6.2.5.1 Market size, by treatment method, 2016 – 2027
6.2.5.1.1 Medications market size, by drug class, 2016 – 2027
6.2.5.1.2 Medications market size, by route of administration, 2016 – 2027
6.2.5.2 Market size, by distribution channel, 2016 – 2027
6.3 Europe
6.3.1 Market size, by country, 2016 – 2027
6.3.2 Market size, by treatment method, 2016 – 2027
6.3.2.1 Medications market size, by drug class, 2016 – 2027
6.3.2.2 Medications market size, by route of administration, 2016 – 2027
6.3.3 Market size, by distribution channel, 2016 – 2027
6.3.4 Germany
6.3.4.1 Market size, by treatment method, 2016 – 2027
6.3.4.1.1 Medications market size, by drug class, 2016 – 2027
6.3.4.1.2 Medications market size, by route of administration, 2016 – 2027
6.3.4.2 Market size, by distribution channel, 2016 – 2027
6.3.5 France
6.3.5.1 Market size, by treatment method, 2016 – 2027
6.3.5.1.1 Medications market size, by drug class, 2016 – 2027
6.3.5.1.2 Medications market size, by route of administration, 2016 – 2027
6.3.5.2 Market size, by distribution channel, 2016 – 2027
6.3.6 UK
6.3.6.1 Market size, by treatment method, 2016 – 2027
6.3.6.1.1 Medications market size, by drug class, 2016 – 2027
6.3.6.1.2 Medications market size, by route of administration, 2016 – 2027
6.3.6.2 Market size, by distribution channel, 2016 – 2027
6.3.7 Italy
6.3.7.1 Market size, by treatment method, 2016 – 2027
6.3.7.1.1 Medications market size, by drug class, 2016 – 2027
6.3.7.1.2 Medications market size, by route of administration, 2016 – 2027
6.3.7.2 Market size, by distribution channel, 2016 – 2027
6.3.8 Spain
6.3.8.1 Market size, by treatment method, 2016 – 2027
6.3.8.1.1 Medications market size, by drug class, 2016 – 2027
6.3.8.1.2 Medications market size, by route of administration, 2016 – 2027
6.3.8.2 Market size, by distribution channel, 2016 – 2027
6.4 Latin America
6.4.1 Market size, by country, 2016 – 2027
6.4.2 Market size, by treatment method, 2016 – 2027
6.4.2.1 Medications market size, by drug class, 2016 – 2027
6.4.2.2 Medications market size, by route of administration, 2016 – 2027
6.4.3 Market size, by distribution channel, 2016 – 2027
6.4.4 Brazil
6.4.4.1 Market size, by treatment method, 2016 – 2027
6.4.4.1.1 Medications market size, by drug class, 2016 – 2027
6.4.4.1.2 Medications market size, by route of administration, 2016 – 2027
6.4.4.2 Market size, by distribution channel, 2016 – 2027
6.4.5 Mexico
6.4.5.1 Market size, by treatment method, 2016 – 2027
6.4.5.1.1 Medications market size, by drug class, 2016 – 2027
6.4.5.1.2 Medications market size, by route of administration, 2016 – 2027
6.4.5.2 Market size, by distribution channel, 2016 – 2027
6.5 Rest of the world
6.5.1 Market size, by country, 2016 – 2027
6.5.2 Market size, by treatment method, 2016 – 2027
6.5.2.1 Medications market size, by drug class, 2016 – 2027
6.5.2.2 Medications market size, by route of administration, 2016 – 2027
6.5.3 Market size, by distribution channel, 2016 – 2027
6.5.4 Australia
6.5.4.1 Market size, by treatment method, 2016 – 2027
6.5.4.1.1 Medications market size, by drug class, 2016 – 2027
6.5.4.1.2 Medications market size, by route of administration, 2016 – 2027
6.5.4.2 Market size, by distribution channel, 2016 – 2027
6.5.5 South Africa
6.5.5.1 Market size, by treatment method, 2016 – 2027
6.5.5.1.1 Medications market size, by drug class, 2016 – 2027
6.5.5.1.2 Medications market size, by route of administration, 2016 – 2027
6.5.5.2 Market size, by distribution channel, 2016 – 2027
Chapter 7 Company Profiles
7.1 Strategy dashboard, 2020
7.2 Vertex Pharmaceuticals Incorporated
7.2.1 Business overview
7.2.2 Financial data
7.2.3 Product landscape
7.2.4 Strategic outlook
7.2.5 SWOT analysis
7.3 Roche
7.3.1 Business overview
7.3.2 Financial data
7.3.3 Product landscape
7.3.4 Strategic outlook
7.3.5 SWOT analysis
7.4 Nestle Health Science
7.4.1 Business overview
7.4.2 Financial data
7.4.3 Product landscape
7.4.4 Strategic outlook
7.4.5 SWOT analysis
7.5 Abbvie
7.5.1 Business overview
7.5.2 Financial data
7.5.3 Product landscape
7.5.4 Strategic outlook
7.5.5 SWOT analysis
7.6 Viatris Inc
7.6.1 Business overview
7.6.2 Financial data
7.6.3 Product landscape
7.6.4 Strategic outlook
7.6.5 SWOT analysis
7.7 Horizon Therapeutics plc
7.7.1 Business overview
7.7.2 Financial data
7.7.3 Product landscape
7.7.4 Strategic outlook
7.7.5 SWOT analysis
7.8 Gilead
7.8.1 Business overview
7.8.2 Financial data
7.8.3 Product landscape
7.8.4 Strategic outlook
7.8.5 SWOT analysis
7.9 Chiesi Farmaceutici
7.9.1 Business overview
7.9.2 Financial data
7.9.3 Product landscape
7.9.4 Strategic outlook
7.9.5 SWOT analysis
7.10 Pharmaxis Ltd
7.10.1 Business overview
7.10.2 Financial data
7.10.3 Product landscape
7.10.4 Strategic outlook
7.10.5 SWOT analysis
7.11 Teva Pharmaceuticals
7.11.1 Business overview
7.11.2 Financial data
7.11.3 Product landscape
7.11.4 Strategic outlook
7.11.5 SWOT analysis
